Teyssedou Lenaic Nathanael
Teyssedou Lenaic Nathanael, PAO, reported a transaction classified as return at Addex Therapeutics Ltd. involving 208974.000000 shares for an estimated $0.00. Reported holdings after the transaction were 393934.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
- Trade date
- Sep 02, 2026
- Filing date
- Sep 04, 2026
How reported position traded is calculated
Not calculated for derivative securities.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
ADXN price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- return Code D
- Identifier
- 0001104659-26-105509 Stock-option (Right to Buy)
- Transaction date
- Sep 02, 2026 Filed Sep 04, 2026, 08:11 PM · 2d delay
- Shares
- 208,974 sh $0.00 per share
- Estimated value
- $0 Computed from shares × price
- Holdings after
- 393,934 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
-6 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - timely_filing+4 points
reporting_delay_days = 2
Filing reported within two business days of the transaction. - derivative_transaction-16 points
is_derivative = true
Derivative exercise rows are less discretionary than open-market purchases.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
PRINCIPAL ACCOUNTING OFFICER
- F1
On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of the options were repriced to $0.032. All of the other terms of the options remain unc…
- F2
The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026.
0 other transactions
0 recent txs